Overview

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before the transplant and tacrolimus and methotrexate after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving antithymocyte globulin together with cyclophosphamide, busulfan, and fludarabine works in treating patients with hematological cancer or kidney cancer undergoing donor stem cell transplant.

Phase:

Phase 2

Details

Lead Sponsor:

Northside Hospital, Inc.

Collaborator:

Blood and Marrow Transplant Group of Georgia

Treatments:

Antilymphocyte Serum
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Methotrexate
Tacrolimus
Thymoglobulin
Vidarabine